LH Stock Analysis: Laboratory of America | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 25.280m USD | 12M Return: 13.5% | US5049221055 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 238M
EPS Trend: 89.7%
Qual. Beats: 3
Rev. Trend: 94.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Labcorp Holdings Inc. is a large-cap U.S. healthcare services company that operates through two main segments: Diagnostics Laboratories and Biopharma Laboratory Services. The Diagnostics Laboratories segment offers a wide range of routine clinical tests, including blood chemistry, urinalysis, blood cell counts, thyroid and PAP tests, hemoglobin A1C, PSA, sexually transmitted disease testing, vitamin D testing, and microbiology cultures, alongside alcohol and substance abuse testing.
Beyond routine diagnostics, the company provides specialty and esoteric testing in areas such as anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, womens health, pharmacogenetics, parentage testing, occupational testing, medical drug monitoring, and kidney stone prevention. Labcorp also offers health and wellness services to employers and managed care organizations, supporting chronic disease management and preventive care initiatives.
Labcorp has expanded into digital health, offering pathology digitization solutions, online platforms for providers, payers, and accountable care organizations (ACOs), as well as patient-facing mobile applications for scheduling visits, completing documentation, and accessing test results. The company has also introduced a Generative AI-enabled test selection tool, reflecting broader industry adoption of artificial intelligence to improve diagnostic decision-making and workflow efficiency.
Its Biopharma Laboratory Services segment serves pharmaceutical, biotechnology, medical device, and diagnostic companies, as well as contract research organizations (CROs), supporting drug development and clinical trials. Labcorp has strategic collaborations with the Childrens Hospital of Philadelphia for pediatric diagnostics, the National Association of Community Health Centers, and the Alliance for Clinical Trials in Oncology, reinforcing its role across both clinical care and biomedical research.
- Diagnostics segment volume growth offsets Medicare reimbursement cuts
- Biopharma Services backlog expansion supports higher-margin revenue mix
- Capital allocation focuses on share buybacks and selective acquisitions
| Net Income: 1.00b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.75 > 1.0 |
| NWC/Revenue: 11.78% < 20% (prev 10.16%; Δ 1.62% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.64b > Net Income 1.00b |
| Net Debt (7.53b) to EBITDA (2.15b): 3.50 < 3 |
| Current Ratio: 1.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.0m) vs 12m ago -2.50% < -2% |
| Gross Margin: 27.85% > 18% (prev 28.14%; Δ -0.29% > 0.5%) |
| Asset Turnover: 78.42% > 50% (prev 74.66%; Δ 3.76% > 0%) |
| Interest Coverage Ratio: 6.41 > 6 (EBIT TTM 1.46b / Interest Expense TTM 227.2m) |
| A: 0.09 (Total Current Assets 3.81b - Total Current Liabilities 2.12b) / Total Assets 18.5b |
| B: 0.47 (Retained Earnings 8.70b / Total Assets 18.5b) |
| C: 0.08 (EBIT TTM 1.46b / Avg Total Assets 18.3b) |
| D: 0.87 (Book Value of Equity 8.61b / Total Liabilities 9.91b) |
| Altman-Z'' = 3.58 = A |
| DSRI: 1.03 (Receivables 2.50b/2.28b, Revenue 14.3b/13.5b) |
| GMI: 1.01 (GM 28.14% / 27.85%) |
| AQI: 1.04 (AQ_t 0.63 / AQ_t-1 0.60) |
| SGI: 1.06 (Revenue 14.3b / 13.5b) |
| TATA: -0.03 (NI 1.00b - CFO 1.64b) / TA 18.5b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at USD 312.15 with a total of 607,853 shares traded. Over the past week, the price has changed by +1.19%, over one month by -2.79%, over three months by +12.67% and over the past year by +13.51%.
Current recommended Stop Loss: 297.60 (which is 4.7% or 2.1 ATR below the current price).
Laboratory of America has received a consensus analysts rating of 4.28. Therefore, it is recommended to buy LH.
- StrongBuy: 11
- Buy: 2
- Hold: 4
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 344.2 | 10.3% |
P/E Trailing = 25.7825
P/E Forward = 16.1551
P/S = 1.7619
P/B = 2.9356
P/EG = 1.214
Revenue TTM = 14.3b USD
EBIT TTM = 1.46b USD
EBITDA TTM = 2.15b USD
Long Term Debt = 5.86b USD (from longTermDebt, last quarter)
Short Term Debt = 185.9m USD (from shortTermDebt, last quarter)
Debt = 7.67b USD (from shortLongTermDebtTotal, last quarter) + Leases 907.6m
Net Debt = 7.53b USD (calculated: Debt 7.67b - CCE 141.8m)
Enterprise Value = 32.8b USD (25.3b + Debt 7.67b - CCE 141.8m)
Interest Coverage Ratio = 6.41 (Ebit TTM 1.46b / Interest Expense TTM 227.2m)
EV/FCF = 28.40x (Enterprise Value 32.8b / FCF TTM 1.16b)
FCF Yield = 3.52% (FCF TTM 1.16b / Enterprise Value 32.8b)
FCF Margin = 8.05% (FCF TTM 1.16b / Revenue TTM 14.3b)
Net Margin = 6.99% (Net Income TTM 1.00b / Revenue TTM 14.3b)
Gross Margin = 27.85% ((Revenue TTM 14.3b - Cost of Revenue TTM 10.4b) / Revenue TTM)
Gross Margin QoQ = 29.80% (prev 26.52%)
Tobins Q-Ratio = 1.77 (Enterprise Value 32.8b / Total Assets 18.5b)
Interest Expense / Debt = 2.96% (Interest Expense 227.2m / Debt 7.67b)
Taxrate = 18.66% (230.2m / 1.23b)
NOPAT = 1.18b (EBIT 1.46b * (1 - 18.66%))
Current Ratio = 1.80 (Total Current Assets 3.81b / Total Current Liabilities 2.12b)
Debt / Equity = 0.89 (Debt 7.67b / totalStockholderEquity, last quarter 8.61b)
Debt / EBITDA = 3.50 (Net Debt 7.53b / EBITDA 2.15b)
Debt / FCF = 6.52 (Net Debt 7.53b / FCF TTM 1.16b)
Total Stockholder Equity = 8.66b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.48% (Net Income 1.00b / Total Assets 18.5b)
RoE = 11.57% (Net Income TTM 1.00b / Total Stockholder Equity 8.66b)
RoCE = 10.02% (EBIT 1.46b / Capital Employed (Equity 8.66b + L.T.Debt 5.86b))
RoIC = 7.20% (NOPAT 1.18b / Invested Capital 16.5b)
WACC = 5.65% (E(25.3b)/V(33.0b) * Re(6.64%) + D(7.67b)/V(33.0b) * Rd(2.96%) * (1-Tc(0.19)))
Discount Rate = 6.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.41 | Cagr: -1.43%
[DCF] Terminal Value 74.21% ; FCFF base≈1.20b ; Y1≈1.12b ; Y5≈1.02b
[DCF] Fair Price = 106.3 (EV 16.2b - Net Debt 7.53b = Equity 8.62b / Shares 81.1m; r=8.35% [WACC [floored]]; 5y FCF grow -8.45% → 2.50% )
EPS Correlation: 89.65 | EPS CAGR: 7.97% | SUE: 3.16 | # QB: 3
Revenue Correlation: 94.16 | Revenue CAGR: 6.01% | SUE: 0.48 | # QB: 0
EPS current Quarter (2026-09-30): EPS=4.65 | Chg30d=-0.08% | Revisions=+0% | Analysts=14
EPS current Year (2026-12-31): EPS=18.35 | Chg30d=+0.01% | Revisions=+40% | GrowthEPS=+11.6% | GrowthRev=+5.7%
EPS next Year (2027-12-31): EPS=19.81 | Chg30d=-0.04% | Revisions=+62% | GrowthEPS=+8.0% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: +58% (up=8, down=1)